MXPA02001587A - Composiciones que incluyen modafinilo para el tratamiento del trastorno de hiperactividad con deficit de atencion y de la fatiga en la esclerosis multiple. - Google Patents

Composiciones que incluyen modafinilo para el tratamiento del trastorno de hiperactividad con deficit de atencion y de la fatiga en la esclerosis multiple.

Info

Publication number
MXPA02001587A
MXPA02001587A MXPA02001587A MXPA02001587A MXPA02001587A MX PA02001587 A MXPA02001587 A MX PA02001587A MX PA02001587 A MXPA02001587 A MX PA02001587A MX PA02001587 A MXPA02001587 A MX PA02001587A MX PA02001587 A MXPA02001587 A MX PA02001587A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
attention deficit
hyperactivity disorder
deficit hyperactivity
treatment
Prior art date
Application number
MXPA02001587A
Other languages
English (en)
Inventor
Thomas E Scammell
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MXPA02001587A publication Critical patent/MXPA02001587A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MXPA02001587A 1999-08-16 2000-08-16 Composiciones que incluyen modafinilo para el tratamiento del trastorno de hiperactividad con deficit de atencion y de la fatiga en la esclerosis multiple. MXPA02001587A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14961299P 1999-08-16 1999-08-16
US09/638,353 US6346548B1 (en) 1999-08-16 2000-08-15 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
PCT/US2000/022338 WO2001012170A2 (en) 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

Publications (1)

Publication Number Publication Date
MXPA02001587A true MXPA02001587A (es) 2003-07-21

Family

ID=26846889

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001587A MXPA02001587A (es) 1999-08-16 2000-08-16 Composiciones que incluyen modafinilo para el tratamiento del trastorno de hiperactividad con deficit de atencion y de la fatiga en la esclerosis multiple.

Country Status (20)

Country Link
US (3) US6346548B1 (es)
EP (1) EP1253918B1 (es)
JP (1) JP5542291B2 (es)
KR (1) KR100728080B1 (es)
CN (1) CN100450475C (es)
AT (1) ATE410157T1 (es)
AU (1) AU778360B2 (es)
BR (1) BR0013555A (es)
CA (2) CA2689735A1 (es)
CY (1) CY1109079T1 (es)
DE (1) DE60040487D1 (es)
DK (1) DK1253918T3 (es)
ES (1) ES2313902T3 (es)
HK (1) HK1051006A1 (es)
IL (2) IL147794A0 (es)
MX (1) MXPA02001587A (es)
NO (1) NO331307B1 (es)
NZ (1) NZ516767A (es)
PT (1) PT1253918E (es)
WO (1) WO2001012170A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
CZ2003529A3 (cs) * 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
EP1401483A1 (en) 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
UA88600C2 (ru) * 2002-09-13 2009-11-10 Сефалон, Інк. Фармацевтическая стандартная доза модафинила и способ лечения adhd
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR045423A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
EP1586560A1 (en) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituted arylmethanesulfinyl derivatives
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
CA2575790A1 (en) * 2004-09-24 2006-03-30 Centre For Addiction And Mental Health The use of a modafinil compound for the treatment of problem gambling
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007093624A2 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
EA200802208A1 (ru) * 2006-05-09 2009-04-28 Бёрингер Ингельхайм Интернациональ Гмбх Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) * 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
US20100010092A1 (en) * 2006-12-19 2010-01-14 Arless Ltd. Use of modafinil to treat restless leg syndrome
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
US9289403B2 (en) * 2007-03-09 2016-03-22 The Board of Trustees of the University of Arizona Use of modafinil to treat spasticity
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
FR2970711B1 (fr) 2011-01-20 2016-03-04 Hopitaux Paris Assist Publique La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
KR102150417B1 (ko) * 2018-08-29 2020-09-01 경북대학교 산학협력단 복외측전시각영역 내 성상세포의 광유전학적 자극을 통한 수면 유도 동물 모델 및 이를 이용한 수면 제어제의 스크리닝 방법
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2707637B1 (fr) 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
CZ20013061A3 (cs) * 1999-02-24 2002-06-12 University Of Cincinnati Pouľití sulfamátových derivátů pro léčbu poruch kontroly impulsů

Also Published As

Publication number Publication date
DK1253918T3 (da) 2008-12-08
ATE410157T1 (de) 2008-10-15
CA2689735A1 (en) 2001-02-22
WO2001012170A2 (en) 2001-02-22
HK1051006A1 (en) 2003-07-18
ES2313902T3 (es) 2009-03-16
US7087647B2 (en) 2006-08-08
JP2003527320A (ja) 2003-09-16
NO20020772L (no) 2002-02-15
IL147794A0 (en) 2002-08-14
KR20020038726A (ko) 2002-05-23
EP1253918B1 (en) 2008-10-08
KR100728080B1 (ko) 2007-06-14
PT1253918E (pt) 2008-11-20
CA2380673A1 (en) 2001-02-22
US20030069313A1 (en) 2003-04-10
US20020082301A1 (en) 2002-06-27
NO20020772D0 (no) 2002-02-15
WO2001012170A3 (en) 2002-09-06
BR0013555A (pt) 2007-03-27
CY1109079T1 (el) 2014-07-02
CN1635875A (zh) 2005-07-06
DE60040487D1 (de) 2008-11-20
JP5542291B2 (ja) 2014-07-09
US6346548B1 (en) 2002-02-12
NZ516767A (en) 2004-03-26
CN100450475C (zh) 2009-01-14
NO331307B1 (no) 2011-11-21
AU778360B2 (en) 2004-12-02
AU6642400A (en) 2001-03-13
EP1253918A2 (en) 2002-11-06
CA2380673C (en) 2010-03-30
US6488164B2 (en) 2002-12-03
IL147794A (en) 2007-07-04

Similar Documents

Publication Publication Date Title
IL147794A0 (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
CA2165824A1 (fr) Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
EP1470146B8 (en) Antibodies against the muc18 antigen
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
WO2003047524A3 (en) Methods and compositions for modulating the immune system and uses thereof
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
EP1556068A4 (en) TREATMENT OF AUTISM AND SIMULTANEOUS DISEASES
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
Panta The possible role of meditation in myofascial pain syndrome: a new hypothesis
SE9701161D0 (sv) New use I
BR0317586A (pt) Compostos para normalização do ciclo sono/vigìlia
CA2418167A1 (en) Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
MY126607A (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
AU4630599A (en) Perfume composition
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
MY131599A (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
WO2001072955A3 (en) Regulation of human nedd1-related protein
He et al. Clinical Reports on Levodopa Administration in Amblyopia
WO1998036758A3 (de) Sauerstoffanionradikale enthaltende therapeutische mittel und deren verwendung zur behandlung von morbus parkinson
Heo et al. A Clinical Study of One Patients Suffering Headache after Administering Banhabaekchulcheonma-tang
TH124101B (th) องค์ประกอบที่ประกอบด้วยโมแดฟินิลสำหรับการรักษาแอทเทนชัน เดฟิซิท ไฮเปอร์แอกทิวิตี้ ดิสออร์เดอร์และความล้าเหตุมัลติเพิลสคลีโรซีส

Legal Events

Date Code Title Description
FG Grant or registration